Видео ютуба по тегу Dual-Targeting

Dual Targeting Schemes
Dual Targeting Schemes
Dr. Bardia on Dual Targeting of the HER2 Receptor
Dr. Bardia on Dual Targeting of the HER2 Receptor
Dual CAR-T Cells Explained: Could Two Targets Be Better Than One? #myeloma
Dual CAR-T Cells Explained: Could Two Targets Be Better Than One? #myeloma
DURGA-1 Trial Update:- BCMA/CD19 Dual-Targeting CAR-T in Myeloma | Shambavi Richard, MD #Tandem26
DURGA-1 Trial Update:- BCMA/CD19 Dual-Targeting CAR-T in Myeloma | Shambavi Richard, MD #Tandem26
ASH 2025 Expert Insights: Dual-Targeting CAR-T in Multiple Myeloma
ASH 2025 Expert Insights: Dual-Targeting CAR-T in Multiple Myeloma
The development of a nanoparticle based, dual targeting approach to overcome apoptotic resistance
The development of a nanoparticle based, dual targeting approach to overcome apoptotic resistance
CIPO2015: Dual Targeting of CD19 & CD22 on B-ALL Using a Single Bispecific Chimeric Antigen Receptor
CIPO2015: Dual Targeting of CD19 & CD22 on B-ALL Using a Single Bispecific Chimeric Antigen Receptor
Assoc Prof Belamy Cheung – A dual targeting novel combination therapy for childhood brain tumours
Assoc Prof Belamy Cheung – A dual targeting novel combination therapy for childhood brain tumours
Dr. Amengual on Dual Targeting With an HDAC 6 Inhibitor and Bortezomib in Lymphoma
Dr. Amengual on Dual Targeting With an HDAC 6 Inhibitor and Bortezomib in Lymphoma
Phase 1 Dual-Targeting FasTCAR-T Cells for First-Line Tx of Transplant-Eligible High-Risk MM
Phase 1 Dual-Targeting FasTCAR-T Cells for First-Line Tx of Transplant-Eligible High-Risk MM
Evaluating dual-targeting CD19/22 CAR-T cells in patients with R/R ALL
Evaluating dual-targeting CD19/22 CAR-T cells in patients with R/R ALL
Challenges of dual-targeted CAR T-cell therapy
Challenges of dual-targeted CAR T-cell therapy
Novel targets and dual-targeting approaches in myeloma
Novel targets and dual-targeting approaches in myeloma
Dual-targeting CD30/PDL1 CAR-T therapy in Hodgkin lymphoma
Dual-targeting CD30/PDL1 CAR-T therapy in Hodgkin lymphoma
Opportunities and challenges for dual-targeting CAR-T therapy in ALL
Opportunities and challenges for dual-targeting CAR-T therapy in ALL
RedirecTT-1 Study: Dual Targeting of BCMA and GPRC5D in RRMM Pts with Teclistamab and Talquetamab
RedirecTT-1 Study: Dual Targeting of BCMA and GPRC5D in RRMM Pts with Teclistamab and Talquetamab
Using dual-targeting CAR-Ts to overcome CAF-induced CAR-T resistance in multiple myeloma
Using dual-targeting CAR-Ts to overcome CAF-induced CAR-T resistance in multiple myeloma
Dual-targeting bispecific antibody alnuctamab in R/R multiple myeloma
Dual-targeting bispecific antibody alnuctamab in R/R multiple myeloma
Overcoming CAR-T cell resistance in MCL: armored CARs, dual-targeting approaches & combinations
Overcoming CAR-T cell resistance in MCL: armored CARs, dual-targeting approaches & combinations
Dual targeting of the cancer metabolome & stress antigens to improve efficacy of engineered T-cells
Dual targeting of the cancer metabolome & stress antigens to improve efficacy of engineered T-cells